Note: Ingredients listed on restricted chemical lists
General Information
Version
2.0
Revision date
2024-06-14
Product name
DECAPOL DEEPCLEAN
1.2.1 Relevant identified uses
Professional use Industrial/Professional use spec
Manufacturer Name
LAFFORT FRANCE SAS
Emergency telephone
+32 70 245 245, 070 245 245, +359 2 9154 233, +385 1 234 8342, +420 224 919 293, +420 224 915 402, +45 82 12 12 12, +33 1 45 42 59 59, +30 2 10 779 3777, +36 80 20 11 99, +353 1 809 2566, +353 1 809 2166, +356 2545 6508, +356 2545 6504, +48 42 63 14 724, +40 21 230 8000, +381 11 360 84 40, +386 522 52 83, 0344 892 0111, +44 20 7188 7188
Icons in SDS
Company Information
company name
LAFFORT FRANCE SAS
e-mail address of the competent person responsible for the Safety Data Sheet
info@laffort.com, laffortitalia@laffort.com, laffortusa@laffort.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Causes serious eye irritation.
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Contains
Protease; Cellulase
Hazard statements
H319 - Causes serious eye irritation.
Precautionary statements
P264 - Wash hands, forearms and face thoroughly after handling. P280 - Wear protective gloves, eye protection. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+P313 - If eye irritation persists: Get medical advice/attention.
Supplemental label elements
EUH208 - Contains Protease(9014-01-1), Cellulase(9012-54-8). May produce an allergic reaction.
2.3 Other hazards
Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or substance(s) are not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
